Related News
Drug contract may see advent of CMO
Print Edition
GERMANY’S Boehringer Ingelheim yesterday signed an agreement to manufacture biopharmaceuticals for Beijing-based biotech company BeiGene in Shanghai, which has been studying plans to allow contract manufacturing of biomedicine.
BI’s newly invested Zhangjiang facility in Shanghai is expected to start producing cancer drugs for BeiGene next year to be used for clinical research purposes, the companies said. The 500 million yuan (US$81.3 million) facility will eventually become BI’s fourth manufacturing plant to support the global market after Germany, Austria and the US.
Shanghai has been considering since 2013 to be the first in China to introduce biophamaceuticals contract manufacturing organization (CMO), which lets a contract manufacturer act as a producer and shipper on behalf of a hiring company.
Hubertus von Baumbach, member of BI’s board of managing directors, said the firm is confident of a CMO license for the Zhangjiang facility, a joint investment with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co, which started last year.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
